CompletedPhase 3NCT01377922
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Studying Lambert-Eaton myasthenic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Catalyst Pharmaceuticals, Inc.
- Principal Investigator
- Charles W Gorodetzky, MD, PhDChief Medical Officer
- Intervention
- Amifampridine Phosphate(drug)
- Enrollment
- 38 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2016
Study locations (14)
- Birmingham, Alabama, United States
- Scottsdale, Arizona, United States
- Los Angeles, California, United States
- Palo Alto, California, United States
- Kansas City, Kansas, United States
- New York, New York, United States
- Lyon, France
- Munich, Bavaria, Germany
- Berlin, Germany
- Pécs, Hungary
- Warsaw, Poland
- Moscow, Russia
- Belgrade, Serbia
- Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01377922 on ClinicalTrials.gov